Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2022

Authors

  • Jan M Bell Australian Group on Antimicrobial Resistance, Adelaide, South Australia, Australia
  • Alicia Fajardo Lubian Westmead Institute for Medical Research, Westmead, New South Wales, Australia; University of Sydney, New South Wales, Australia
  • Sally R Partridge Westmead Institute for Medical Research, Westmead, New South Wales, Australia; University of Sydney, New South Wales, Australia; Westmead Hospital, Westmead, New South Wales, Australia
  • Thomas Gottlieb University of Sydney, New South Wales, Australia; Department of Microbiology and Infectious Diseases, Concord Hospital, Concord, New South Wales, Australia
  • Jennifer Robson Department of Microbiology, Sullivan Nicolaides Pathology, Bowen Hills, Queensland
  • Jonathan R Iredell Westmead Institute for Medical Research, Westmead, New South Wales, Australia; University of Sydney, New South Wales, Australia ; Westmead Hospital, Westmead, New South Wales, Australia
  • Denise A Daley Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
  • Geoffrey W Coombs Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia; Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

DOI:

https://doi.org/10.33321/cdi.2023.47.69

Keywords:

Australian Group on Antimicrobial Resistance (AGAR), antimicrobial resistance, bacteraemia, gram-negative, Escherichia coli, Enterobacter, Klebsiella

Abstract

The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. The 2022 survey was the tenth year to focus on blood stream infections caused by Enterobacterales, and the eighth year where Pseudomonas aeruginosa and Acinetobacter species were included. Fifty-five hospitals Australia-wide participated in 2022.

The 2022 survey tested 9,739 isolates, comprising Enterobacterales (8,773; 90.1%), P. aeruginosa (840; 8.6%) and Acinetobacter species (126; 1.3%), using commercial automated methods. The results were analysed using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2023). Key resistances included resistance to the third-generation cephalosporin ceftriaxone in 12.7%/12.7% (CLSI/EUCAST criteria) of Escherichia coli and in 6.6%/6.6% of Klebsiella pneumoniae complex. Resistance rates to ciprofloxacin were 13.7%/13.7% for E. coli; 7.8%/7.8% for K. pneumoniae complex; 5.3%/5.3% for Enterobacter cloacae complex; and 4.3%/10.0% for P. aeruginosa. Resistance rates to piperacillin-tazobactam were 2.8%/5.9%; 2.9%/8.7%; 18.3%/27.2%; and 6.1%/14.7% for the same four species, respectively. Twenty-nine Enterobacterales isolates from 28 patients were shown to harbour a carbapenemase gene: 18 blaIMP-4; four blaNDM-5; three blaNDM-1; one blaOXA-181; one blaOXA-244; one blaNDM-1 + blaOXA-181; and one blaNDM-5 + blaOXA-181. Transmissible carbapenemase genes were also detected among two Acinetobacter baumannii complex isolates (blaOXA-23) and one P. aeruginosa (blaNDM-1) in the 2022 survey.

Downloads

Download data is not yet available.

References

Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 33rd ed. CLSI supplement M100. Wayne, PA: CLSI; 3 March 2023.

The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 13.1. Basel: EUCAST; 29 June 2023. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_13.1_Breakpoint_Tables.pdf.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81. doi: https://doi.org/10.1111/j.1469-0691.2011.03570.x.

Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor. San Francisco: Github; 2020. Available from: https://github.com/tseemann/nullarbor.

Seemann T. Abricate. San Francisco: Github; 2020. Available from: https://github.com/tseemann/abricate.

National Center for Biotechnology Information (NCBI). AMRFinderPlus. [Website.] Bethesda; United States National Library of Medicine, NCBI: 2020. Available from: https://ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/.

Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, Keane JA et al. ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads. Microb Genom. 2017;3(10):e000131. doi: https://doi.org/10.1099/mgen.0.000131.

Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A et al. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Res. 2020;48(D1):D517–25. doi: https://doi.org/10.1093/nar/gkz935.

Turnidge JD, Gottlieb T, Mitchell D, Pearson J, Bell JM, on behalf of the Australian Group for Antimicrobial Resistance (AGAR). Gram-negative Survey: 2011 Antimicrobial Susceptibility Report. AGAR; 2012. Available from: http://agargroup.org.au/wp-content/uploads/2017/08/AGAR-GNB11-Report-FINAL.pdf.

European Centre for Disease Prevention and Control (ECDC). European Antimicrobial Resistance Surveillance Network (EARS-Net). [Webpage.] Solna: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/about-us/networks/disease-networks-and-laboratory-networks/ears-net-data.

Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2019;63(7):63:e00355-19. doi: https://doi.org/10.1128/AAC.00355-19.

Sheng WH, Badal RE, Hsueh PR, on behalf of the SMART Program. Distribution of extended-spectrum ß-lactamases, AmpC ß-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013;57(7):2981–8. doi: https://doi.org/10.1128/AAC.00971-12.

ECDC. Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual epidemiological report for 2021. Solna: ECDC; 17 November 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2021.

ECDC/World Health Organization (WHO) Regional Office for Europe. Antimicrobial resistance surveillance in Europe 2023 – 2021 data. Solna: ECDC; 14 April 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2023-2021-data.

Australian Commission on Safety and Quality in Health Care (ASCQHC). National Safety and Quality Health Service Standards. 2nd ed; updated May 2021. Sydney: ACSQHC; May 2021. Available from: https://www.safetyandquality.gov.au/publications-and-resources/resource-library/national-safety-and-quality-health-service-standards-second-edition.

Downloads

Published

16/11/23

How to Cite

Bell, Jan M, Alicia Fajardo Lubian, Sally R Partridge, Thomas Gottlieb, Jennifer Robson, Jonathan R Iredell, Denise A Daley, and Geoffrey W Coombs. 2023. “Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-Negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2022 ”. Communicable Diseases Intelligence 47 (November). https://doi.org/10.33321/cdi.2023.47.69.

Issue

Vol. 47 (2023)

Section

Annual report

Categories

License

Copyright (c) 2023 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>